![]() Selected from a crowded field as Co-Lead Counsel, we achieved a landmark $79 million common fund settlement for the benefit of E*Trade’s shareholders in an action relating to the misrepresentation of the risk associated with E*Trade’s investment in subprime mortgage-backed securities. E*TRADE Financial Corp., et al., 07 CV 8538 (S.D.N.Y. Class C Shareholder Litigation resulted in a payment of $522 million to shareholders and overall benefit of over $3 billion to Google’s minority shareholders. (Nassau Cnty., New York Supreme Court 2011) “…a model for how great legal profession should conduct itself.” Justice Timothy S. ![]() Took on real contingency risk and… obtained an injunction…” Vice Chancellor J. “laintiff’s went the distance… did real work… She directs the Firm’s Portfolio Monitoring Services, assisting clients in identifying losses in their securities portfolios that were caused by corporate wrongdoing. Kulesa’s practice focuses on securities litigation and institutional investor relations. To receive more information, please fill out the form. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss in Meridian Bioscience you have until January 16, 2018to request that the Court appoint you as lead plaintiff. Food and Drug Administration and Centers for Disease Control and Prevention issued a press release “warning Americans that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results…” Then on July 13, 2017, the FDA issued a statement that as part of an “aggressive investigation” the FDA had inspected Magellan Diagnostics’ facility and issued a report including “several inspectional observations that may be violations of federal law.” and its subsidiary Magellan Diagnostics, Inc. On March 24, 2016, Meridian completed its acquisition of Magellan Biosciences, Inc. ![]() ![]() manufactured lead testing systems that provide inaccurate results. The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that its subsidiary, Magellan Diagnostics, Inc. 1:17-cv-00774-SJD) was filed in the USDC for the Southern District of Ohio. (NASDAQ: VIVO) who purchased shares between Maand July 13, 2017. Levi & Korsinky, LLP announces it filed a complaint on behalf of shareholders of Meridian Bioscience, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |